Syndax Pharmaceuticals, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 14.15 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.26B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Details
| Name | Syndax Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 298 |
| Founded | 2005 |
| Ipo Date | 2016-03-03 |
| Ceo | Michael Metzger |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US87164F1057 |
| Cusip | 87164F105 |
| Cik | 0001395937 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Michael A. Metzger M.B.A. | Chief Executive Officer and Director |
| Keith Alan Goldan CPA | Chief Financial Officer, Treasurer and Principal Accounting Officer |
| Luke J. Albrecht J.D. | General Counsel and Corporate Secretary |
| Steven Closter | Chief Commercial Officer |
| Dr. Nicholas A.J. Botwood B.Sc., MBBS | Head of Research and Development and Chief Medical Officer |
| Dr. Peter Ordentlich B.Sc., Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Richard A. Heyman Ph.D. | Co-Founder |
| Dr. Michael Downes Ph.D. | Co-Founder |
| Sharon Klahre | Vice President of Investor Relations and Communications |
| Averi Price | Senior Vice President of Legal and Chief Compliance Officer |
Contact
| Address | 730 Third Avenue, 9th Floor, New York, New York 10017, United States |
| Phone | 781 419 1400 |
| Website | https://syndax.com |